title: Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up.
abstract: BACKGROUND
  Whether corticosteroid and immunosuppressive therapy may be safely withdrawn in patients with proliferative lupus nephritis is still unclear.
  
  
  METHODS
  In 32 patients with biopsy-proven proliferative lupus nephritis previously put into remission, therapy was gradually tapered off.
  
  
  RESULTS
  When immunosuppressive therapy was stopped (median: 38 months; 25th-75th percentile: 24-81 months, after biopsy), 24 patients were in complete remission and eight had a median proteinuria of 1.05 g/24 h (25th-75th percentile: 0.91-1.1 g/24 h) with normal renal function. After stopping therapy, patients were followed for a median of 203 months (25th-75th percentile: 116-230 months). Fifteen patients (Group 1) never developed lupus activity. The other 17 patients (Group 2) developed lupus exacerbations in a median of 34 months (25th-75th percentile: 29-52 months) after stopping therapy and were re-treated. The only significant differences between the two groups were the longer median durations of treatment, 57 months (25th-75th percentile: 41.5-113.5 months) vs 30 months (25th-75th percentile: 18-41 months; P<0.009), and remission, 24 months (25th-75th percentile: 18-41) vs 12 months (25th-75th percentile: 7-20 months; P<0.02), before stopping therapy in Group 1 than in Group 2. At last follow-up, 12 patients of Group 1 were in complete remission, two had mild proteinuria and one had died. In Group 2, one patient died, 14 were in complete remission, one had mild proteinuria and in another patient serum creatinine doubled.
  
  
  CONCLUSIONS
  Some patients with severe lupus nephritis who enter stable remission can be maintained without any specific treatment for many years. Those patients who have new flares can again go into remission with an appropriate treatment. The longer the treatment and remission before withdrawal, the lower the risk of relapse.
authors.affiliation: Division of Nephrology, Ospedale Maggiore IRCCS, Via Commenda 15, 20122 Milan, Italy. gmoroni@policlinico.mi.it
authors.forename: Gabriella
authors.initials: G
authors.lastname: Moroni
authors.forename: Beniamina
authors.initials: B
authors.lastname: Gallelli
authors.forename: Silvana
authors.initials: S
authors.lastname: Quaglini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Banfi
authors.forename: Emilio
authors.initials: E
authors.lastname: Rivolta
authors.forename: Piergiorgio
authors.initials: P
authors.lastname: Messa
authors.forename: Claudio
authors.initials: C
authors.lastname: Ponticelli
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008181:Lupus Nephritis / Q000188:drug therapy*; D008297:Male; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents